Condition: Malignant Pleural Effusions · NSCLC Stage IV · Sponsor: Wuhan YZY Biopharma Co., Ltd.
This is a phase 1/phase 2, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of M701 in patients with treatment of malignant pleural effusions caused by NSCLC.
This description comes directly from the study's public registry record.
ShaoYi Huang · 86-027-82668440 · huangshaoyi@yzybio.com
Li Huang · 13647219857 · huangli@yzybio.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05543330